Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Differences in backbone structure between angiotensin II agonists and type I antagonists

J M Matsoukas1, G Agelis, A Wahhab

  • 1Department of Chemistry, University of Patras, Greece.

Journal of Medicinal Chemistry
|November 10, 1995
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interactions of the potent synthetic AT1 antagonist analog BV6 with membrane bilayers and mesoporous silicate matrices.

Biochimica et biophysica acta·2013
Same author

Chemistry and quality of Hibiscus (Hibiscus sabdariffa) for developing the natural-product industry in Senegal.

Journal of food science·2009
Same author

Normal basilar artery structure and biaxial mechanical behaviour.

Computer methods in biomechanics and biomedical engineering·2009
Same author

New target tissue for food-borne virus detection in oysters.

Letters in applied microbiology·2009
Same author

Increased ROS generation and SOD activity in heteroplasmic tissues of transmitochondrial mice with A3243G mitochondrial DNA mutation.

Genetics and molecular research : GMR·2008
Same author

Effect of mouse thymic medullary epithelial cell line on thymocyte development and functional maturationin vivo.

Science in China. Series C, Life sciences·2008

New angiotensin II (ANGII) antagonists were synthesized using O-methyl-L-homoserine and delta-methoxy-L-norvaline. These compounds show potent antagonist activity, with specific structural modifications crucial for maintaining efficacy and revealing conformational differences from ANGII agonists.

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Structural Biology

Background:

  • Angiotensin II (ANGII) plays a critical role in cardiovascular regulation.
  • Development of selective ANGII antagonists is a key therapeutic strategy.
  • Understanding structure-activity relationships (SAR) and conformational properties is essential for drug design.

Purpose of the Study:

  • To synthesize and characterize novel Type I ANGII antagonists.
  • To investigate the impact of specific amino acid substitutions at positions 4 and 8 on antagonist activity.
  • To elucidate conformational differences between ANGII agonists and Type I antagonists.

Main Methods:

  • Solid-phase peptide synthesis for analog preparation.
  • Reverse-phase high-performance liquid chromatography (HPLC) for purification.

Related Experiment Videos

  • Bioassay in rat uterus to determine antagonist activity (pA2 values).
  • Nuclear Overhauser Effect (NOE) spectroscopy for conformational analysis.

    • Main Results:

    • Several novel ANGII antagonists incorporating O-methyl-L-homoserine [HSer(gamma-OMe)] and delta-methoxy-L-norvaline [Nva(delta-OMe)] at position 8 were successfully synthesized and exhibited significant antagonist activities (pA2 values up to 7.6).
    • Modifications at position 4 of [Sar1]ANGII analogs with delta-hydroxy-L-norvaline [Nva(delta-OH)], Nva(delta-OMe), 4'-carboxyphenylalanine [Phe(4'-COOH)], and 4'-(trifluoromethyl)phenylalanine [Phe(4'-CF3)] resulted in compounds with primarily agonist activity, indicating the importance of the tyrosine hydroxyl group.
    • Conformational studies revealed the absence of the Tyr-Ile-His bend in Type I antagonists, a feature present in ANGII agonists, suggesting a distinct backbone conformation.

    Conclusions:

    • Replacement of Ile8 with HSer(gamma-OMe) or Nva(delta-OMe) maintains Type I antagonist activity.
    • The tyrosine hydroxyl group in [Sar1]ANGII is critical, and its replacement with negatively charged or electronegative groups abolishes activity.
    • A significant conformational difference, specifically the lack of the Tyr-Ile-His bend, distinguishes Type I ANGII antagonists from agonists.